fashion -WSS

fashion

author：entertainment 2025-09-03 07:54:23 - browse：4452

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： CRISPR gene editing developments we’re watching in 2024

WSS

Editas, Vertex strike deal on CRISPR

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Medicare drug price negotiation hasn't dried up venture capital

Grail spinoff by Illumina should end disastrous merger attempt

Albert Bourla of Pfizer: worst biopharma CEO of 2023

hotspot

fashion

hotspot

Walensky prepares to leave CDC — and Congress — behind

Medicare drug price negotiation hasn't dried up venture capital

Duchenne breakthrough therapy leaves behind pioneering families

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Continuity nursing helped my family in our darkest PICU moments

After a decade, new Gardasil ad campaign gets it (mostly) right

Guidelines to prevent youth baseball injuries need more muscle

Christmas in the PICU brings some surprising joy

Guidelines to prevent youth baseball injuries need more muscle

Are infertility treatments 'essential' during the Covid

entertainment

Christmas in the PICU brings some surprising joy

Medicare Advantage beneficiaries sue Humana over algorithm use

SEC charges former device maker CEO with $41 million fraud

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Why health records don't always know when patients are dead

focus

focus

explore

leisure time